Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich Licenses Polyplus-transfection's ZNA Technology

NEW YORK (GenomeWeb News) – Sigma-Aldrich said today that it will make and market oligonucleotides developed by Polyplus-transfection, a Strasbourg, France-based firm, under a new worldwide license agreement.

The agreement covers Polyplus-transfection's Zip Nucleic Acid (ZNA) oligonucleotides, which are designed for use in research and diagnostic applications.

ZNA oligonucleotides have attached cationic units that increase their sensitivity and ability to detect mutations. They are used in PCR probes and primers, siRNA, and in vitro micro RNA detection, Sigma-Aldrich said.

"The increased performances seen for ZNA oligonucleotides offer advantages for our customers, and we look forward to making this technology available to our global customer base," Sigma Custom Products VP Theresa Creasey said in a statement.

Financial terms of the agreement were not released.

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.